| Literature DB >> 28739788 |
Alicia Galar1,2, Maricela Valerio3,2, Patricia Muñoz3,2,4,5, Luis Alcalá3,2,5, Xandra García-González2,6, Almudena Burillo3,2,4, María Sanjurjo2,6, Santiago Grau7,8, Emilio Bouza1,2,4,5.
Abstract
Linezolid serum trough (Cmin) and peak (Cmax) levels were determined prospectively in 90 patients. Adequate exposure was defined as a Cmin of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid Cmin levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.Entities:
Keywords: drugs for Gram-positive bacteria; linezolid; therapeutic drug monitoring
Mesh：
Substances：
Year: 2017 PMID： 28739788 PMCID： PMC5610525 DOI： 10.1128/AAC.00687-17
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191